Feugiat nulla facilisis at vero eros et curt accumsan et iusto odio dignissim qui blandit praesent luptatum zzril.
+ (123) 1800-453-1546
info@example.com

Related Posts

Title Image

Research

  • Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study. Smit MA, van Pelt GW, Roodvoets A, Meershoek- Klein Kranenbarg E, Putter H, et al.. JMIR Res Protoc. 2019 Jun 14;8(6):e13464
  • e-Learning for Instruction and to Improve Reproducibility of Scoring Tumor-Stroma Ratio in Colon Carcinoma: Performance and Reproducibility Assessment in the UNITED Study. Smit MA, van Pelt GW, Dequeker EM, Al Dieri R, Tollenaar RA, van Krieken JHJ, Mesker WE; UNITED Group. JMIR Form Res. 2021 Mar 19;5(3):e19408

2021

  • Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer: a cohort study. Smit MA, van Pelt GW, Terpstra V, Putter H, Tollenaar RAEM, Mesker WE, van Krieken JHJM. Int J Colorectal Dis. 2021 Sep 17.
  • The value of the tumour-stroma ratio for predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer: a case control study. Liang Y, Zhu Y, Lin H, Zhang S, Li S, Huang Y, Liu C, Qu J, Liang C, Zhao K, Li Z, Liu Z. BMC Cancer. 2021 Jun 25;21(1):729
  • Increasing Embryonic Morphogen Nodal Expression Suggests Malignant Transformation in Colorectal Lesions and as a Potential Marker for CMS4 Subtype of Colorectal Cancer. Wang X, Liu S, Cao H, Li X, Rong Y, Liu G, Du H, Shen H. Pathol Oncol Res. 2021 Mar 10;27:587029
  • Clinicopathological Significances of Tumor-Stroma Ratio (TSR) in Colorectal Cancers: Prognostic Implication of TSR Compared to Hypoxia-Inducible Factor-1α Expression and Microvessel Density. Kang G, Pyo JS, Kim NY, Kang DW. Curr Oncol. 2021 Mar 22;28(2):1314-1324.
  • Standardized Assessment of the Tumor-Stroma Ratio in Colorectal Cancer: Interobserver Validation and Reproducibility of a Potential Prognostic Factor. Souza da Silva RM, Queiroga EM, Paz AR, Neves FFP, Cunha KS, Dias EP. Clin Pathol. 2021 Feb 11;14:2632010X21989686.
  • The Effect of Quality Control on Accuracy of Digital Pathology Image Analysis. Wright AI, Dunn CM, Hale M, Hutchins GGA, Treanor DE. IEEE J Biomed Health Inform. 2021 Feb;25(2):307-314.

2020

  • Tumour-stroma ratio has poor prognostic value in non-pedunculated T1 colorectal cancer: A multi-centre case-cohort study. Dang H, van Pelt GW, Tollenaar RA, Hardwick JC, Hawinkels LJ, Moons LM, Lacle MM, Mesker WE, Boonstra JJ; Dutch T1 CRC Working Group. United European Gastroenterol J. 2020 Nov 19:2050640620975324
  • Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer. Zunder SM, Perez-Lopez R, Gelderblom H, Tollenaar RA, Nuciforo P, Wasser MN, Mesker WE. Eur J Radiol. 2020 Oct 13;133:109345
  • The role of artificial intelligence to quantify the tumour-stroma ratio for survival in colorectal cancer. Smit MA, Mesker WE. EBioMedicine. 2020 Nov;61:103070
  • Multiparametric MRI-based radiomics signature for preoperative estimation of tumor-stroma ratio in rectal cancer. Cai C, Hu T, Gong J, Huang D, Liu F, Fu C, Tong T. Eur Radiol. 2020 Nov 12. doi: 10.1007/s00330-020-07403-6. Epub ahead of print. PMID: 33180166.
  • Artificial intelligence quantified tumour-stroma ratio is an independent predictor for overall survival in resectable colorectal cancer. Zhao K, Li Z, Yao S, Huang Y, Liang C, Liu Z. EBioMedicine. 2020 Nov;61:103054
  • Filling the Gap between Microscopic and Automated Analysis of the Tumor-Stroma Ratio. Van Pelt G, Tollenaar R, Mesker W. Ann Colorectal Res. 2020;8(1):1-4
  • The significance of stromal collagen organization in cancer tissue; an in-depth discussion of literature. Zunder SM, Gelderblom H, Tollenaar RA, Mesker WE. Critical Reviews in Oncology/Hematology. 2020 July, 102907
  • Prognostic and Predictive Value of the Tumor-Stroma Ratio in STAGE II Colon Cancer. Zunder SM, Gerger A, Gelderblom H, Tollenaar RA, Filipits M, et al. Clinical Oncology and Research. 2020 April.
  • Tumor proportion in colon cancer: results from a semiautomatic image analysis approach. Martin B, Banner BM, Schäfer EM, Mayr P, Anthuber M, et al. Virchows Arch. 2020 Feb 19
  • Preoperative, biopsy-based assessment of the tumour microenvironment in patients with primary operable colorectal cancer. Park JH, van Wyk H, McMillan DC, Edwards J, Orange C, et al. J Pathol Clin Res. 2020 Jan;6(1):30-39
  • Association of the tumour stroma percentage in the preoperative biopsies with lymph node metastasis in colorectal cancer. Fu M, Chen D, Luo F, Li M, Wang Y, et al. Br J Cancer 122, 388–396 (2020).

2019

  • Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial. Zunder S, van der Wilk P, Gelderblom H, Dekker T, Mancao C, et al. Cell Oncol (Dordr). 2019 Oct;42(5):717-725.
  • The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer. van Wyk HC, Roseweir A, Alexander P, Park JH, Horgan PG, et al. Ann Surg Oncol. 2019 Oct 11.
  • Tumour Budding and Tumour Stroma Ratio are Reliable Predictors for Death and Recurrence in Elderly Stage I Colon Cancer Patients. Zengin M. Pathol Res Pract. 2019 Nov;215(11):152635
  • The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer. Roseweir AK, Clark J, McSorley ST, vanWyk HC, Quinn JA, et al. Int J Cancer. 2019 May 1;144(9):2320-2329.
  • Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer. Geessink OGF, Baidoshvili A, Klaase JM, Ehteshami Bejnordi B, Litjens GJS, et al. Cellular Oncology. 2019 February.

2018

  • Scoring the tumour-stroma ratio in colon cancer: Procedure and recommendations. van Pelt GW, Kjaer-Frifeldt S, van Krieken JHJM, Al Dieri R, Morreau H, Tollenaar RAEM, et al. Virchows Archiv. 2018 Oct; 473(4):405-412
  • Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer. Zunder SM, van Pelt GW, Gelderblom HJ, Mancao C, Putter H, Tollenaar RA, et al. British Journal of Cancer. 2018
  • The tumour-stroma ratio in colon cancer; the biological role and its prognostic impact. van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van Krieken J, Tollenaar R, et al. Histopathology. 2018 Aug;73(2):197-206.
  • The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial. Huijbers A, van Pelt GW, Kerr RS, Johnstone EC, Tollenaar R, Kerr DJ, et al. J Surg Oncol. 2018 Apr;117(5):1043-1048.
  • Does heterogeneity matter in the estimation of tumour budding and tumour stroma ratio in colon cancer? Eriksen AC, Andersen JB, Lindebjerg J, dePont Christensen R, Jansen TF, Kjaer-Frifeldt S, et al. Diagn Pathology. 2018 Mar;13(1):20
  • Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. Hutchins GGA, Treanor D, Wright A, Handley K, Magill L, Tinkler-Hundal E, et al. 2018;72(3):391-404.
  • The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. Eriksen AC, Sorensen FB, Lindebjerg J,Hager H, dePont Christensen R, Kjaer-Frifeldt S, et al. International Journal of Colorectal Disease. 2018 Aug;33(8):115-1124
  • Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Ubink I, van Eden WJ, Snaebjornsson P, Kok NFM, van Kuik J, et al. Br J Surg. 2018 Jan;105(2):e204-e211

2017

  • Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer. Jakubowska K, Kisielewski W, Kanczuga-Koda L, Koda M, Famulski W. Oncol Lett. 2017;14(3):3869-77.
  • High tumor stroma proportion is a worse prognostic factor in colorectal cancer. Flam J, Gugic D, Bensic M, Tomic S, Rajc J.Acta Clin Croat. 2017 Jan;56(1)73-79.
  • Prognostic markers for colorectal cancer; estimating ploidy and stroma. Danielsen HE, Hveem TS, Domingo E, Pradhan M, Kleppe A, Syvertsen RA, et al. Ann Oncol. 2017.
  • Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. Hansen TF, Kjaer-Frifeldt S, Lindebjerg J, Rafaelsen SR, Jensen LH, Jakobsen A, et al. Acta Oncol. 2017:1-6.
  • Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study. Hynes SO, Coleman HG, Kelly PJ, Irwin S, O’Neill RF, Gray RT, et al. 2017;71(1):12-26.
  • Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. Park JH, van Wyk H, Roxburgh CSD, Horgan PG, Edwards J, McMillan DC. Br J Cancer. 2017;116(11):1444-50.
  • Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: A retrospective cohort study. Scheer R, Baidoshvili A, Zoidze S, Elferink MAG, Berkel AEM, Klaase JM, et al. World J Gastrointest Oncol. 2017;9(12):466-74.

2016

  • Stroma-High Lymph Node Involvement Predicts Poor Survival More Accurately for Patients with Stage III Colon Cancer. Van Pelt GW, Hansen TF,Bastiaannet E, Frifeldt SK, Van Krieken JH, et al. J Med Surg Pathol 2016; 1:116.
  • Are disseminated tumor cells in bone marrow and tumor-stroma ratio clinically applicable for patients undergoing surgical resection of primary colorectal cancer? The Leiden MRD study. Vogelaar FJ, van Pelt GW, van Leeuwen AM, Willems JM, Tollenaar RA, Liefers GJ, et al. Cell Oncol (Dordr). 2016;39(6):537-44.

2014

  • The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS. Ann Oncol. 2014;25(3):644-51.

2013

  • The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, et al. Ann Oncol. 2013;24(1):179-85

2010

  • The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, et al. Br J Cancer. 2010;102(10):1519-23.

2009

  • Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ, et al. Cell Oncol. 2009;31(3):169-78.

2007

  • The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, et al. Cell Oncol. 2007;29(5):387-98.

2021

  • Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer. Hagenaars SC, de Groot S, Cohen D, Dekker TJA, Charehbili A, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Pijl H, Putter H, Tollenaar RAEM, Kroep JR, Mesker WE; Dutch Breast Cancer Research Group (BOOG). Int J Cancer. 2021 Sep 1;149(5):1181-1188
  • Toward a quantitative method for estimating tumour-stroma ratio in breast cancer using polarized light microscopy. Sprenger J, Murray C, Lad J, Jones B, Thomas G, Nofech-Mozes S, Khorasani M, Vitkin A. Biomed Opt Express. 2021 May 10;12(6):3241-3252
  • Prognostic value of Tumor Stroma Ratio in Triple Negative Breast Cancer. Zakhartseva LM, Yanovytska MA. Wiad Lek. 2021;74(3 cz 2):565-571.

2020

  • Tumour Stroma Ratio Assessment Using Digital Image Analysis Predicts Survival in Triple Negative and Luminal Breast Cancer. Millar EK, Browne LH, Beretov J, Lee K, Lynch J, Swarbrick A, Graham PH. Cancers (Basel). 2020 Dec 13;12(12):E3749.
  • Chemotherapy resistance and stromal targets in breast cancer treatment: a review. van der Spek YM, Kroep JR, Tollenaar RAEM, Mesker WE. Mol Biol Rep. 2020 Oct 1. doi: 10.1007/s11033-020-05853-1. Epub ahead of print. PMID: 33006013.
  • 70-Gene Signature and Tumor-Stroma Ratio Select Different Groups of Patients with Breast Cancer at Risk for Recurrence. Smit MA, van Steenhoven JEC, Tollenaar RAEM, van Dalen T, van Diest PJ, et al. Journal of Surgery and Research 3 (2020): 112-118.
  • The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. Vangangelt KMH, Green AR, Heemskerk IMF, Cohen D, van Pelt GW, et al. Int J Cancer. 2020 Apr 15;146(8):2296-2304
  • Does Tumor Stroma Ratio of Breast Cancer Trucut Biopsy Determine Response to Neoadjuvant Therapy? Mallya V, Singh V, Kaur N, Yadav P, Mandal S, et al. Indian J Pathol Microbiol, 63 (Supplement), S113-S116 Feb 2020
  • The intra-tumoural stroma in patients with breast cancer increases with age. Vangangelt KMH, Kramer CJH, Bastiaannet E, Putter H, Cohen D, van Pelt GW, et al. Breast Cancer Res Treat. 2020 Jan;179(1):37-45

2019

  • The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review. Kramer CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, Tollenaar RAEM, Mesker WE. Breast Cancer Res Treat. 2019 Jan;173(1):55-64

2018

  • The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients. Vangangelt KMH, Tollenaar LSA, van Pelt GW, de Kruijf EM, Dekker TJA, Kuppen PJK , et al. Int J Cancer. 2018 Jul 6.
  • Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma. Vangangelt KMH, van Pelt GW, Engels CC, Putter H, Liefers GJ, Smit V, et al. Breast Cancer Res Treat. 2018 Apr;168(3):601-612.

2017

  • The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study. Roeke T, Sobral-Leite M, Dekker TJA, Wesseling J, Smit V, Tollenaar R, et al. Breast Cancer Res Treat. 2017;166(2):435-45.

2014

  • The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. Gujam FJ, Edwards J, Mohammed ZM, Going JJ, McMillan DC. Br J Cancer. 2014;111(1):157-65
  • The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer.Downey CL, Simpkins SA, White J, Holliday DL, Jones JL, Jordan LB, et al. Br J Cancer  2014; 110 (7):1744-1747.
  • Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Dekker TJ, van de Velde CJ, van Pelt GW, Kroep JR, Julien JP, Smit VT, et al. Breast Cancer Res Treat. 2013;139(2):371-9.

2012

  • The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA. Eur J Surg Oncol. 2012;38(4):307-13.

2011

  • Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, et al. Breast Cancer Res Treat. 2011;125(3):687-96.

2020

  • The prognostic value of the tumor-stroma ratio in squamous cell lung cancer, a cohort study. Smit MA, Philipsen MWH, Postmus PE, Putter H, Tollenaar RAEM, Cohen D, Mesker WE. Cancer Treatment and Research Communications. 2020 Nov; 25: 2468-2942

2019

  • Intratumoral heterogeneity as measured using the tumor-stroma ratio and PET texture analyses in females with lung adenocarcinomas differs from that of males with lung adenocarcinomas or squamous cell carcinomas. Koh YW, Lee D, Lee SJ, et al. Medicine (Baltimore). 2019 Mar;98(11):e14876

2018

  • The ratio of cancer cells to stroma within the invasive area is histologic prognostic parameter of lung adenocarcinoma. Ichikawa T, Aokage K, Sugano M, Miyoshi T, Kojima M, Fujii S, et al. Lung Cancer 2018; 118:30-35.

2017

  • Tumour-stroma ratio (TSR) in non-small cell lung cancer (NSCLC) patients after lung resection is a prognostic factor for survival. Xi K, Wen Y, Zhu C, Yu X, Qin R, Zhang X, et al. J Thorac Dis 2017; 9(10):4017-4026.

2015

  • Tumor-stroma ratio is an independent predictor for survival in NSCLC. Zhang T, Xu J, Shen H, Dong W, Ni Y, Du J. Int J Clin Exp Pathol. 2015;8(9):11348-55.

2013

  • [Tumor-stroma ratio is an independent prognostic factor of non-small cell lung cancer].Wang Z, Liu H, Zhao R, Zhang H, Liu C, Song Y. Zhongguo Fei Ai Za Zhi. 2013;16(4):191-6.

2021

  • Tumour-stroma ratio is a valuable prognostic factor for oral tongue squamous cell carcinoma. Kang J, Su M, Xu Q, Wang C, Yuan X, Han Z. Oral Dis. 2021 Aug 29.
  • Tumor-stroma ratio is a crucial histological predictor of occult cervical lymph node metastasis and survival in early-stage (cT1/2N0) oral squamous cell carcinoma. Huang S, Cai H, Song F, Zhu Y, Hou C, Hou J. Int J Oral Maxillofac Surg. 2021 Aug 16:S0901-5027(21)00269-1.
  • Associations Between ADC and Tumor Infiltrating Lmphocytes, Tumor-Stroma Ratio and Vimentin Expression in Head and Neck Squamous Cell Cancer. Meyer HJ, Höhn AK, Surov A. Acad Radiol. 2021 Jun 30:S1076-6332(21)00222-1
  • Assessment of Histological Features in Squamous Cell Carcinoma Involving Head and Neck Skin and Mucosa. Caruntu A, Moraru L, Lupu M, Ciubotaru DA, Dumitrescu M, Eftimie L, Hertzog R, Zurac S, Caruntu C, Voinea OC. J Clin Med. 2021 May 27;10(11):2343
  • Histogram parameters derived from T1 and T2 weighted images correlate with tumor infiltrating lymphocytes and tumor-stroma ratio in head and neck squamous cell cancer. Meyer HJ, Höhn AK, Surov A. Magn Reson Imaging. 2021 May 7:S0730-725X(21)00077-1.
  • Proposal of a scoring system for predicting pathological risk based on a semiautomated analysis of whole slide images in oral squamous cell carcinoma. Sung YE, Kim MS, Lee YS. Head Neck. 2021 May;43(5):1581-1591.
  • Biopsy quality is essential for preoperative prognostication in oral tongue cancer. Bello IO, Wennerstrand PM, Suleymanova I, Siponen M, Qannam A, Nieminen P, Leivo I, Almangush A, Salo T. APMIS. 2021 Mar;129(3):118-127.

2020

  • Clinicopathological correlation of tumor-stroma ratio and inflammatory cell infiltrate with tumor grade and lymph node metastasis in squamous cell carcinoma of buccal mucosa and tongue in 41 cases with review of literature. Rani P, Gupta AJ, Mehrol C, Singh M, Khurana N, Passey JC. J Cancer Res Ther. 2020 Apr-Jun;16(3):445-451.
  • Addition of the tumour-stroma ratio to the 8th edition American Joint Committee on Cancer staging system improves survival prediction for patients with oral tongue squamous cell carcinoma. Mascitti M, Zhurakivska K, Togni L, Santarelli A, Troiano G et al. Histopathology. 2020 Jul 7. doi: 10.1111/his.14202. Epub ahead of print. PMID: 32633006.
  • Histological characteristics of early-stage oral tongue cancer in young versus older patients: A multicenter matched-pair analysis. Bello IO, Almangush A, Heikkinen I, Haglund C, Coletta RD, et al. Oral Dis. 2020 Jan 29
  • Prognostication of oral squamous cell carcinoma patients based on tumor-stroma ratio and tumor budding. Dourado MR, Miwa KYM, Hamada GB, Paranaíba LMR, Sawazaki-Calone Í, et al. Histopathology. 2020 Jan 27

2019

  • Prognostic significance of tumor budding, tumor-stroma ratio, cell nests size, and stroma type in laryngeal and pharyngeal squamous cell carcinomas. Karpathiou G, Vieville M, Gavid M, Camy F, Dumollard JM, et al. Head Neck. 2019 Jan;1-10

2018

  • Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers. Almangush A, Heikkinen I, Bakhti N, Makinen LK, Kauppila JH, Pukkila M, et al. Histopathology. 2018.
  • Prognostic impact of tumor-stroma ratio in oral squamous cell carcinoma – A pilot study. Niranjan KC, Sarathy NA. Annals of Diagnostic Pathology 2018; 35:56-61.

2014

  • The tumor-stroma ratio is an independent predictor for survival in nasopharyngeal cancer. Oncol Res Treat. Zhang XL, Jiang C, Zhang ZX, Liu F, Zhang F, Cheng YF. 2014;37(9):480-4.

2021

  • The prognostic value of tumor-stromal ratio combined with TNM staging system in esophagus squamous cell carcinoma. He R, Li D, Liu B, Rao J, Meng H, Lin W, Fan T, Hao B, Zhang L, Lu Z, Feng H, Zhang Z, Yuan J, Geng Q. J Cancer. 2021 Jan 1;12(4):1105-1114.

2020

  • The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer. Van Pelt GW, Krol JA, Lips IM, Peters FP, van Klaveren D, et al. Clin Transl Radiat Oncol. 2019 Nov 27;20:39-44

2016

  • Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial. Hale MD, Nankivell M, Hutchins GG, Stenning SP, Langley RE, Mueller W, et al. Oncotarget. 2016;7(47):77565-75.

2012

  • Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. Wang K, Ma W, Wang J, Yu L, Zhang X, Wang Z, et al. J Thorac Oncol. 2012;7(9):1457-61.

2011

  • Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies. Courrech Staal EF, Smit VT, van Velthuysen ML, Spitzer-Naaykens JM, Wouters MW, Mesker WE, et al. Eur J Cancer. 2011;47(3):375-82.

2010

  • The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Courrech Staal EF, Wouters MW, van Sandick JW, Takkenberg MM, Smit VT, Junggeburt JM, et al. Eur J Cancer. 2010;46(4):720-8.

2020

  • Gastric cancer nodal tumour-stroma ratios influence prognosis. Huang J, Yang B, Tan J, Zeng J, Zhong L, Liu X, Han F. Br J Surg. 2020 Oct 14

2019

  • Tumour-stroma ratio and 5-year mortality in gastric adenocarcinoma: a systematic review and meta-analysis. Kemi N, Eskuri M, Kauppila JH. Sci Rep. 2019 Nov 5;9(1):16018

2018

  • Tumor microenvironmental factors have prognostic significances in advanced gastric cancer.Ahn B, Chae YS, Kim CH, Lee Y, Lee JH, Kom JY. APMIS (Journal of pathology, microbiology and immunology). Sept 2018
  • Tumour-stroma ratio and prognosis in gastric adenocarcinoma.Kemi N, Eskuri M, Herva A, Leppänen J, Huhta H, Helminen O, et al. British Journal of Cancer. 2018

2017

  • The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system.Peng C, Liu J, Yang G, Li Y. J Gastroenterol. 2017.
  • Tumor-Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients.Aurello P, Berardi G, Giulitti D, Palumbo A, Tierno SM, Nigri G, et al. Surgeon. 2017 Dec; 15(6):329-335.
  • Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas.Lee D, Ham IH, Son SY, Han SU, Kim YB, Hur H.Gastric Cancer. 2017 Jul;20(4):591-601.

2021

  • Magnetic Resonance Radiomics and Machine-learning Models: An Approach for Evaluating Tumor-stroma Ratio in Patients with Pancreatic Ductal Adenocarcinoma. Meng Y, Zhang H, Li Q, Liu F, Fang X, Li J, Yu J, Feng X, Lu J, Bian Y, Shao C. Acad Radiol. 2021 Sep 22:S1076-6332(21)00369-X.

2020

  • Pros and Cons: High Proportion of Stromal Component Indicates Better Prognosis in Patients With Pancreatic Ductal Adenocarcinoma-A Research Based on the Evaluation of Whole-Mount Histological Slides. Li B, Wang Y, Jiang H, Li B, Shi X, Gao S, Ni C, Zhang Z, Guo S, Xu J, Jin G. Front Oncol. 2020 Aug 21;10:1472.
  • Prognostic effects of histology-based tumour microenvironment scores in resected distal bile duct cancer. Hwang HW, Kim JY, Lee SE, Choi YS, Hong SH, Lee TJ, Kim MK, Park ES, Hong SA. Histopathology. 2020 Sep;77(3):402-412.
  • Tumour budding and tumour-stroma ratio in hepatocellular carcinoma. Kairaluoma V, Kemi N, Pohjanen VM, Saarnio J, Helminen O. Br J Cancer. 2020 Jul;123(1):38-45. doi: 10.1038/s41416-020-0847-1.

2019

  • Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Leppänen J, Lindholm V, Isohookana J, Haapasaari KM, Karihtala P, et al. Pancreas. 2019 Jan;48(1):43-48.

2017

  • Prognostic significance of the tumor-stroma ratio in gallbladder cancer. Li H, Yuan SL, Han ZZ, Huang J, Cui L, et al. Neoplasma 64; 2017.

2015

  • Tumor-stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation. Lv Z, Cai X, Weng X, Xiao H, Du C, Cheng J, et al. Surgery 2015;158(1):142-50.

2020

  • The tumor-stroma ratio is an independent predictor of survival in patients with 2018 FIGO stage IIIC squamous cell carcinoma of the cervix following primary radical surgery. Zong L, Zhang Q, Kong Y, Yang F, Zhou Y, et al. Gynecol Oncol. 2020 Mar;156(3):676-681

2019

  • Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer. Lou E, Vogel RI, Hoostal S, et al. JAMA Oncol. 2019;5(8):1222-1224.

2015

  • Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer. Chen Y, Zhang L, Liu W, Liu X. Biomed Res Int. 2015;2015:589301.
  • Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery. Pongsuvareeyakul T, Khunamornpong S, Settakorn J, Sukpan K, Suprasert P, Intaraphet S, Siriaunkgul S. Asian Pac J Cancer Prev 2015; 16 (10):4363-4368.
  • The prognostic significance of tumour-stroma ratio in endometrial carcinoma. Panayiotou H, Orsi NM, Thygesen HH, Wright AI, Winder M, Hutson R, et al. BMC Cancer. 2015;15:955.

2014

  • Tumor-stroma ratio is an independent predictor for survival in early cervical carcinoma. Liu J, Liu J, Li J, Chen Y, Guan X, Wu X, et al. Gynecol Oncol. 2014;132(1):81-6.

2019

  • The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma. Zou MX, Zheng BW, Liu FS, Wang XB, Hu JR, Huang W, et al. Neurosurgery. 2019 Sep 9.

Meta-analysis

  • Prognostic Value of Tumor-Stroma Ratio in Rectal Cancer: A Systematic Review and Meta-analysis. Zhu Y, Jin Z, Qian Y, Shen Y, Wang Z. Front Oncol. 2021 May 26;11:685570
  • Clinical significance of tumor-stroma ratio in head and neck cancer: a systematic review and meta-analysis. Almangush A, Alabi RO, Troiano G, Coletta RD, Salo T, Pirinen M, Mäkitie AA, Leivo I. BMC Cancer. 2021 Apr 30;21(1):480.
  • Tumor-stroma ratio (TSR) as a potential novel predictor of prognosis in digestive system cancers: A meta-analysis. Zhang R, Song W, Wang K, Zou S. Clin Chim Acta. 2017;472:64-8.
  • Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis.Wu J, Liang C, Chen M, Su W. Oncotarget. 2016 Oct 18;7(42):68954-68965.

Reviews

  • The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review. Kramer CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, Tollenaar RAEM, Mesker WE. Breast Cancer Res Treat. 2018 Oct
  • The tumour-stroma ratio in colon cancer; the biological role and its prognostic impact. van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van Krieken J, Tollenaar R, et al. Histopathology. 2018 Aug;73(2):197-206.

2020

  • 70-Gene Signature and Tumor-Stroma Ratio Select Different Groups of Patients with Breast Cancer at Risk for Recurrence. Smit MA, van Steenhoven JEC, Tollenaar RAEM, van Dalen T, van Diest PJ, et al. Journal of Surgery and Research 3 (2020): 112-118
  • Filling the Gap between Microscopic and Automated Analysis of the Tumor-Stroma Ratio. Van Pelt G, Tollenaar R, Mesker W. Ann Colorectal Res. 2020;8(1):1-4.
  • The significance of stromal collagen organization in cancer tissue; an in-depth discussion of literature. Zunder SM, Gelderblom H, Tollenaar RA, Mesker WE. Critical Reviews in Oncology/Hematology. 2020 July, 102907
  • Prognostic and Predictive Value of the Tumor-Stroma Ratio in STAGE II Colon Cancer. Zunder SM, Gerger A, Gelderblom H, Tollenaar RA, Filipits M, et al. Clinical Oncology and Research. 2020 April;
  • The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. Vangangelt KMH, Green AR, Heemskerk IMF, Cohen D, van Pelt GW, et al. Int J Cancer. 2020 Apr 15;146(8):2296-2304
  • The intra-tumoural stroma in patients with breast cancer increases with age. Vangangelt KMH, Kramer CJH, Bastiaannet E, Putter H, Cohen D, van Pelt GW, et al. Breast Cancer Res Treat. 2020 Jan;179(1):37-45

2019

  • The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer. Van Pelt GW, Krol JA, Lips IM, Peters FP, van Klaveren D, et al. Clin Transl Radiat Oncol. 2019 Nov 27;20:39-44
  • Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial. Zunder S, van der Wilk P, Gelderblom H, Dekker T, Mancao C, et al. Cell Oncol (Dordr). 2019 Oct;42(5):717-725.
  • The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review. Kramer CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, Tollenaar RAEM, et al. Breast Cancer Res Treat. 2019 Jan;173(1):55-64

2018

  • Scoring the tumour-stroma ratio in colon cancer: Procedure and recommendations. van Pelt GW, Kjaer-Frifeldt S, van Krieken JHJM, Al Dieri R, Morreau H, Tollenaar RAEM, et al. Virchows Archiv. 2018 Oct; 473(4):405-412
  • Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer. Zunder SM, van Pelt GW, Gelderblom HJ, Mancao C, Putter H, Tollenaar RA, et al. British Journal of Cancer. 2018
  • The tumour-stroma ratio in colon cancer; the biological role and its prognostic impact. van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van Krieken J, Tollenaar R, et al. Histopathology. 2018 Aug;73(2):197-206.
  • The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients. Vangangelt KMH, Tollenaar LSA, van Pelt GW, de Kruijf EM, Dekker TJA, Kuppen PJK , et al. Int J Cancer. 2018 Jul 6.
  • The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial.Huijbers A, van Pelt GW, Kerr RS, Johnstone EC, Tollenaar R, Kerr DJ, et al. J Surg Oncol. 2018 Apr;117(5):1043-1048.
  • Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma. Vangangelt KMH, van Pelt GW, Engels CC, Putter H, Liefers GJ, Smit V, et al. Breast Cancer Res Treat. 2018 Apr;168(3):601-612.

2017

  • The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study. Roeke T, Sobral-Leite M, Dekker TJA, Wesseling J, Smit V, Tollenaar R, et al. Breast Cancer Res Treat. 2017;166(2):435-45.

2016

  • Stroma-High Lymph Node Involvement Predicts Poor Survival More Accurately for Patients with Stage III Colon Cancer. Van Pelt GW, Hansen TF,Bastiaannet E, Frifeldt SK, Van Krieken JH, et al. J Med Surg Pathol 2016; 1:116.
  • Are disseminated tumor cells in bone marrow and tumor-stroma ratio clinically applicable for patients undergoing surgical resection of primary colorectal cancer? The Leiden MRD study. Vogelaar FJ, van Pelt GW, van Leeuwen AM, Willems JM, Tollenaar RA, Liefers GJ, et al. Cell Oncol (Dordr). 2016;39(6):537-44.

2013

  • Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Dekker TJ, van de Velde CJ, van Pelt GW, Kroep JR, Julien JP, Smit VT, et al. Breast Cancer Res Treat. 2013;139(2):371-9.
  • The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, et al. Ann Oncol. 2013;24(1):179-85

2011

  • Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies. Courrech Staal EF, Smit VT, van Velthuysen ML, Spitzer-Naaykens JM, Wouters MW, Mesker WE, et al. Eur J Cancer. 2011;47(3):375-82.
  • Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, et al. Breast Cancer Res Treat. 2011;125(3):687-96.

2010

  • The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Courrech Staal EF, Wouters MW, van Sandick JW, Takkenberg MM, Smit VT, Junggeburt JM, et al. Eur J Cancer. 2010;46(4):720-8.

2009

  • Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ, et al. Cell Oncol. 2009;31(3):169-78.

2007

  • The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, et al. Cell Oncol. 2007;29(5):387-98.

2020

  • The tumor-stroma ratio is an independent predictor of survival in patients with 2018 FIGO stage IIIC squamous cell carcinoma of the cervix following primary radical surgery. Zong L, Zhang Q, Kong Y, Yang F, Zhou Y, et al. Gynecol Oncol. 2020 Mar;156(3):676-681
  • Does Tumor Stroma Ratio of Breast Cancer Trucut Biopsy Determine Response to Neoadjuvant Therapy? Mallya V, Singh V, Kaur N, Yadav P, Mandal S, et al. Indian J Pathol Microbiol, 63 (Supplement), S113-S116 Feb 2020
  • Tumor proportion in colon cancer: results from a semiautomatic image analysis approach. Martin B, Banner BM, Schäfer EM, Mayr P, Anthuber M, et al. Virchows Arch. 2020 Feb 19
  • Prognostication of oral squamous cell carcinoma patients based on tumor-stroma ratio and tumor budding. Dourado MR, Miwa KYM, Hamada GB, Paranaíba LMR, Sawazaki-Calone Í, et al. Histopathology. 2020 Jan 27
  • Histological characteristics of early-stage oral tongue cancer in young versus older patients: A multicenter matched-pair analysis. Bello IO, Almangush A, Heikkinen I, Haglund C, Coletta RD, et al. Oral Dis. 2020 Jan 29
  • Preoperative, biopsy-based assessment of the tumour microenvironment in patients with primary operable colorectal cancer. Park JH, van Wyk H, McMillan DC, Edwards J, Orange C, et al. J Pathol Clin Res. 2020 Jan;6(1):30-39
  • Association of the tumour stroma percentage in the preoperative biopsies with lymph node metastasis in colorectal cancer. Fu M, Chen D, Luo F, Li M, Wang Y, et al. Br J Cancer 122, 388–396 (2020).

2019

  • Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer. Lou E, Vogel RI, Hoostal S, et al. JAMA Oncol. 2019;5(8):1222-1224
  • Tumour-stroma ratio and 5-year mortality in gastric adenocarcinoma: a systematic review and meta-analysis. Kemi N, Eskuri M, Kauppila JH. Sci Rep. 2019 Nov 5;9(1):16018
  • The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer. van Wyk HC, Roseweir A, Alexander P, Park JH, Horgan PG, et al. Ann Surg Oncol. 2019 Oct 11.
  • Tumour Budding and Tumour Stroma Ratio are Reliable Predictors for Death and Recurrence in Elderly Stage I Colon Cancer Patients. Zengin M. Pathol Res Pract. 2019 Nov;215(11):152635
  • The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer. Roseweir AK, Clark J, McSorley ST, vanWyk HC, Quinn JA, et al. Int J Cancer. 2019 May 1;144(9):2320-2329.
  • The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma. Zou MX, Zheng BW, Liu FS, Wang XB, Hu JR, Huang W, et al. Neurosurgery. 2019 Sep 9.
  • Intratumoral heterogeneity as measured using the tumor-stroma ratio and PET texture analyses in females with lung adenocarcinomas differs from that of males with lung adenocarcinomas or squamous cell carcinomas. Koh YW, Lee D, Lee SJ. Medicine (Baltimore). 2019 Mar;98(11):e14876
  • Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Leppänen J, Lindholm V, Isohookana J, Haapasaari KM, Karihtala P, et al. Pancreas. 2019 Jan;48(1):43-48.
  • Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer. Geessink OGF, Baidoshvili A, Klaase JM, Ehteshami Bejnordi B, Litjens GJS, et al. Accepted February 2019 in Cellular Oncology.
  • Prognostic significance of tumor budding, tumor-stroma ratio, cell nests size, and stroma type in laryngeal and pharyngeal squamous cell carcinomas. Karpathiou G, Vieville M, Gavid M, Camy F, Dumollard JM, et al. Head Neck. 2019 Jan;1-10

2018

  • Does heterogeneity matter in the estimation of tumour budding and tumour stroma ratio in colon cancer? Eriksen AC, Andersen JB, Lindebjerg J, dePont Christensen R, Jansen TF, Kjaer-Frifeldt S, et al. Diagn Pathology. 2018 Mar;13(1):20
  • Tumor microenvironmental factors have prognostic significances in advanced gastric cancer. Ahn B, Chae YS, Kim CH, Lee Y, Lee JH, Kom JY. APMIS (Journal of pathology, microbiology and immunology). Sept 2018
  • Tumour-stroma ratio and prognosis in gastric adenocarcinoma. Kemi N, Eskuri M, Herva A, Leppänen J, Huhta H, Helminen O, et al. British Journal of Cancer. 2018
  • Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers. Almangush A, Heikkinen I, Bakhti N, Makinen LK, Kauppila JH, Pukkila M, et al. Histopathology. 2018.
  • Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. Hutchins GGA, Treanor D, Wright A, Handley K, Magill L, Tinkler-Hundal E, et al. Histopathology. 2018;72(3):391-404.
  • The ratio of cancer cells to stroma within the invasive area is histologic prognostic parameter of lung adenocarcinoma. Ichikawa T, Aokage K, Sugano M, Miyoshi T, Kojima M, Fujii S, et al. Lung Cancer 2018; 118:30-35.
  • The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. Eriksen AC, Sorensen FB, Lindebjerg J,Hager H, dePont Christensen R, Kjaer-Frifeldt S, et al. International Journal of Colorectal Disease. 2018 Aug;33(8):115-1124
  • Prognostic impact of tumor-stroma ratio in oral squamous cell carcinoma – A pilot study. Niranjan KC, Sarathy NA. Annals of Diagnostic Pathology 2018; 35:56-61.
  • Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Ubink I, van Eden WJ, Snaebjornsson P, Kok NFM, van Kuik J, et al. Br J Surg. 2018 Jan;105(2):e204-e211

2017

  • High tumor stroma proportion is a worse prognostic factor in colorectal cancer. Flam J, Gugic D, Bensic M, Tomic S, Rajc J.Acta Clin Croat. 2017 Jan;56(1)73-79.
  • Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer. Jakubowska K, Kisielewski W, Kanczuga-Koda L, Koda M, Famulski W. Oncol Lett. 2017;14(3):3869-77.
  • Prognostic markers for colorectal cancer; estimating ploidy and stroma. Danielsen HE, Hveem TS, Domingo E, Pradhan M, Kleppe A, Syvertsen RA, et al. Ann Oncol. 2017.
  • Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. Hansen TF, Kjaer-Frifeldt S, Lindebjerg J, Rafaelsen SR, Jensen LH, Jakobsen A, et al. Acta Oncol. 2017:1-6.
  • Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study. Hynes SO, Coleman HG, Kelly PJ, Irwin S, O’Neill RF, Gray RT, et al. Histopathology. 2017;71(1):12-26.
  • Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. Park JH, van Wyk H, Roxburgh CSD, Horgan PG, Edwards J, McMillan DC. Br J Cancer. 2017;116(11):1444-50.
  • The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system.Peng C, Liu J, Yang G, Li Y. J Gastroenterol. 2017.
  • Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: A retrospective cohort study. Scheer R, Baidoshvili A, Zoidze S, Elferink MAG, Berkel AEM, Klaase JM, et al. World J Gastrointest Oncol. 2017;9(12):466-74.
  • Tumor-stroma ratio (TSR) as a potential novel predictor of prognosis in digestive system cancers: A meta-analysis. Zhang R, Song W, Wang K, Zou S. Clin Chim Acta. 2017;472:64-8.
  • Tumour-stroma ratio (TSR) in non-small cell lung cancer (NSCLC) patients after lung resection is a prognostic factor for survival. Xi K, Wen Y, Zhu C, Yu X, Qin R, Zhang X, et al. J Thorac Dis 2017; 9(10):4017-4026.
  • Prognostic significance of the tumor-stroma ratio in gallbladder cancer. Li H, Yuan SL, Han ZZ, Huang J, Cui L, Jiang CQ, Zhang Y. Neoplasma 64; 2017.
  • Tumor-Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients.Aurello P, Berardi G, Giulitti D, Palumbo A, Tierno SM, Nigri G, et al. Surgeon. 2017 Dec; 15(6):329-335.
  • Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas. Lee D, Ham IH, Son SY, Han SU, Kim YB, Hur H.Gastric Cancer. 2017 Jul;20(4):591-601.

2016

  • Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial. Hale MD, Nankivell M, Hutchins GG, Stenning SP, Langley RE, Mueller W, et al. Oncotarget. 2016;7(47):77565-75.
  • Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis. Wu J, Liang C, Chen M, Su W. Oncotarget. 2016 Oct 18;7(42):68954-68965.

2015

  • Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer. Chen Y, Zhang L, Liu W, Liu X. Biomed Res Int. 2015;2015:589301.
  • Tumor-stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation. Lv Z, Cai X, Weng X, Xiao H, Du C, Cheng J, et al. Surgery 2015;158(1):142-50.
  • Tumor-stroma ratio is an independent predictor for survival in NSCLC. Zhang T, Xu J, Shen H, Dong W, Ni Y, Du J. Int J Clin Exp Pathol. 2015;8(9):11348-55.
  • Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery. Pongsuvareeyakul T, Khunamornpong S, Settakorn J, Sukpan K, Suprasert P, Intaraphet S, Siriaunkgul S. Asian Pac J Cancer Prev 2015; 16 (10):4363-4368.
  • The prognostic significance of tumour-stroma ratio in endometrial carcinoma. Panayiotou H, Orsi NM, Thygesen HH, Wright AI, Winder M, Hutson R, et al. BMC Cancer. 2015;15:955.

2014

  • The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. Gujam FJ, Edwards J, Mohammed ZM, Going JJ, McMillan DC. Br J Cancer. 2014;111(1):157-65.
  • Tumor-stroma ratio is an independent predictor for survival in early cervical carcinoma. Liu J, Liu J, Li J, Chen Y, Guan X, Wu X, et al. Gynecol Oncol. 2014;132(1):81-6.
  • The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS. Ann Oncol. 2014;25(3):644-51.
  • The tumor-stroma ratio is an independent predictor for survival in nasopharyngeal cancer. Oncol Res Treat. Zhang XL, Jiang C, Zhang ZX, Liu F, Zhang F, Cheng YF. 2014;37(9):480-4.
  • The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer.Downey CL, Simpkins SA, White J, Holliday DL, Jones JL, Jordan LB, et al. Br J Cancer  2014; 110 (7):1744-1747.

2013

  • [Tumor-stroma ratio is an independent prognostic factor of non-small cell lung cancer]. Wang Z, Liu H, Zhao R, Zhang H, Liu C, Song Y. Zhongguo Fei Ai Za Zhi. 2013;16(4):191-6.

2012

  • The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA. Eur J Surg Oncol. 2012;38(4):307-13.
  • Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. Wang K, Ma W, Wang J, Yu L, Zhang X, Wang Z, et al. J Thorac Oncol. 2012;7(9):1457-61.

2010

  • The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, et al. Br J Cancer. 2010;102(10):1519-23.